Working… Menu
Trial record 2 of 8 for:    auditory brainstem implant | Child

Feasibility Study of Auditory Brainstem Implant in Young Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01850225
Recruitment Status : Withdrawn
First Posted : May 9, 2013
Last Update Posted : March 18, 2015
House Clinic, Inc.
Children's Hospital Los Angeles
Information provided by (Responsible Party):
House Research Institute

Brief Summary:
Current treatment options for bilateral profoundly deaf children, diagnosed with inner ear anatomical abnormalities are limited, and in the case of absent cochleas, non-existent. An auditory brainstem implant (ABI) places an electrode close to the auditory nucleus in the brainstem. Children aged 2 - 5 who are not candidates for a cochlear implant, or who did not demonstrate benefit from a cochlear implant, will be implanted with an ABI and followed for 1 year for safety and a total of 3 years for preliminary efficacy. This is a feasibility study to determine the safety of the ABI.

Condition or disease Intervention/treatment Phase
Bilateral Cochlear Aplasia Bilateral Cochlear Nerve Deficiency Bilateral Cochlear Ossification Secondary to Meningitis Device: Auditory brainstem implant Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Feasibility Study of the Placement, Use, and Safety of the Nucleus 24 Auditory Brainstem Implant in Non-Neurofibromatosis Type 2 (NF2) Pediatric Patients
Study Start Date : October 2013
Estimated Primary Completion Date : September 2015
Estimated Study Completion Date : September 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Device implantation
Implantation of device
Device: Auditory brainstem implant
Other Name: Cochlear Corporation Nucleus 24

Primary Outcome Measures :
  1. Number of Serious Adverse Events [ Time Frame: 12-month post-activation ]
    Count of the number of expected serious adverse events must not exceed that known to occur in pediatric retrosigmoid craniotomy and Count of the number of unexpected serious adverse events must not exceed 2 in the first 5 children.

Secondary Outcome Measures :
  1. Access to sound at a level (dB) and within the frequency range (500-4000 Hz), known to be associated with speech [ Time Frame: 3 years post-activation ]
    ability to detect sounds

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   2 Years to 5 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Bilateral profound deafness due to cochlear aplasia, cochlear nerve deficiency, or ossification secondary to meningitis
  • If previously received a cochlear implant, must demonstrate lack of benefit from that device

Exclusion Criteria:

  • Medical contraindication to craniotomy/intracranial surgery
  • Severe cognitive or developmental delays

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01850225

Layout table for location information
United States, California
House Research Institute CARE Center
Los Angeles, California, United States, 90057
Sponsors and Collaborators
House Research Institute
House Clinic, Inc.
Children's Hospital Los Angeles
Layout table for investigator information
Principal Investigator: Eric Wilkinson, MD House Research Institute
Principal Investigator: Laurie Eisenberg, PhD House Research Institute

Layout table for additonal information
Responsible Party: House Research Institute Identifier: NCT01850225     History of Changes
Other Study ID Numbers: Ped ABI
First Posted: May 9, 2013    Key Record Dates
Last Update Posted: March 18, 2015
Last Verified: October 2013
Additional relevant MeSH terms:
Layout table for MeSH terms
Central Nervous System Diseases
Nervous System Diseases